Karyopharm Therapeutics
KPTI
155 hedge funds and large institutions have $1.32B invested in Karyopharm Therapeutics in 2020 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 65 increasing their positions, 33 reducing their positions, and 23 closing their positions.
133% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $6.38M
97% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 33
91% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 23
14% more funds holding
Funds holding: 136 → 155 (+19)
1% more capital invested
Capital invested by funds: $1.31B → $1.32B (+$13.4M)
0.04% more ownership
Funds ownership: 6.31% → 6.36% (+0.04%)
56% less funds holding in top 10
Funds holding in top 10: 9 → 4 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$26.6M |
| 2 |
BlackRock
New York
|
+$21M |
| 3 |
Goldman Sachs
New York
|
+$20.5M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$18.8M |
| 5 |
D.E. Shaw & Co
New York
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$62.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$27M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$13.6M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$11.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.36M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DWA
176
Dorsey Wright & Associates
Pasadena,
California
| – | -$18K | -61 | Closed |
|
|
EWA
177
Evolution Wealth Advisors
Aventura,
Florida
| – | -$14K | -49 | Closed |
|
178
AssetMark Inc
Concord,
California
| – | -$2K | -6 | Closed |
|
KPTI Hedge Fund Activity: Q2 2020 in Review
155 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2020, worth a combined $1.32B — up 1% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new KPTI positions and 23 closed out — a net gain of 21 holders — while 65 added to existing stakes and 33 trimmed.
The largest buyer was State Street, adding an estimated $26.6M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $62.5M sold.
- 155 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2020, up from 136 in Q1 2020.
- Funds reported $1.32B of Karyopharm Therapeutics stock for Q2 2020, up 1% quarter-over-quarter.
- 44 funds opened new Karyopharm Therapeutics positions in Q2 2020 and 23 closed out, a net change of +21 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2020 was State Street, an estimated $26.6M added.
- The largest Karyopharm Therapeutics seller in Q2 2020 was Janus Henderson Group, an estimated $62.5M sold.
Based on aggregated 13F filings for Q2 2020.